Company intelligence / Profile preview
Beroni Group
- Ownership
- Private
- Development stage
- Phase 1
Overview
Beroni Group has a diversified pipeline with programs in immune cell therapies and anti-cancer drug development. It collaborates internationally on clinical research and has commercialized diagnostic assays for infectious diseases. The company’s e-commerce business supports the distribution of pharmaceutical and healthcare products in Asia-Pacific markets. Its anti-cancer drug PENAO has entered clinical development through partnerships with academic institutions.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Cell therapies (immune cell therapy)Small molecules (anti-cancer drugs such as PENAO)Diagnostic assays (e.g., rRT-PCR for infectious diseases)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Beroni Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beroni Group.